Evaluation of the Proliferative Index as a Prognostic Factor in Diffuse Large Cell Lymphoma: Correlation with the International Index

References

• Fisher R I, Gaynor E R, Dahlberg S, Oken M M, Grogan T M, Mize E M, Glick J H, Coltman C A, Jr, Miller T P. Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non‐Hodgkin's lymphoma. N Engl J Med 1993; 328: 1002–1006
   PubMed Web of Science ®Google Scholar
• Shipp M A, Mauch P M, Harris N L. Non‐Hodgkin's lymphomas. Cancer: Principles and Practice of Oncologyed 5, V T DeVita, Jr, S Hellman, S A Rosenberg. Lippincott, Philadelphia, PA 1997; vol 2: 2204
   Google Scholar
• The Non‐Hodgkin's Lymphoma Prognostic Factors Project. Development of a predictive model for aggressive lymphoma: The International NHL Prognostic Factors Project. N Engl J Med 1993; 329: 987–994
   PubMed Web of Science ®Google Scholar
• Ansell S M, Habermann T M, Kurtin P J, Witzig T E, Chen M G, Li C Y, Inwards D J, Colgan J P. Predictive capacity of the International Prognostic Factor Index in patients with peripheral T‐cell lymphoma. J Clin Oncol 1997; 15: 2296–2301
   PubMed Web of Science ®Google Scholar
• Lopez‐Guillermo A, Montserrat E, Bosch F, Terol M, Campo E, Rozman C. Applicability of the international index for aggressive lymphomas to patients with low‐grade lymphoma. J Clin Oncol 1994; 12: 1343–1348
   PubMed Web of Science ®Google Scholar
• Shipp M A. Prognostic factors in aggressive non‐Hodgkin's lymphoma: Who has high risk disease?. Blood 1994; 83: 1165
   PubMed Web of Science ®Google Scholar
• Donhuijsen K. Mitoses in non‐Hodgkin's lymphomas: Frequency and prognostic relevance. Path Res Pract 1987; 182: 352–357
   PubMed Web of Science ®Google Scholar
• Costa A, Bonadonna G, Villa E, Valagussa P, Silvestrini R. Labeling index as a prognostic marker in non‐Hodgkin's lymphomas. J Natl Cancer Inst 1981; 66: 1–5
   PubMed Web of Science ®Google Scholar
• Witzig T E, Gonchoroff N J, Greipp P R, Katzmann J, Stenson M, Habermann T, Colgan J P, Therneau T M, Banks P M. Rapid S‐phase determination of non‐Hodgkin's lymphomas with the use of an immunofluorescence bromodeox‐yuridine labelling index procedure. Am J Clin Pathol 1989; 91: 298–301
   PubMed Web of Science ®Google Scholar
• Costa A, Mazzini G, Bino G D, Silvestrini R. DNA content and kinetic characteristics of non‐Hodgkin's lymphoma: Determined by flow cytometry and autoradiography. Cyromety 1981; 2: 185–188
   PubMedGoogle Scholar
• Braylan R C, Diamond L W, Powell M L, Harty‐Golder B. Percentage of cells in the S‐phase of the cell cycle in human lymphoma determined by flow cytometry: Correlation with labeling index and patient survival. Cytometry 1980; 1: 171–174
   PubMedGoogle Scholar
• Roos G, Dige U, Lenner P, Lindh J, Johansson H. Prognostic significance of DNA‐analysis by flow cytometry in non‐Hodgkin's lymphoma. Hematol Oncol 1985; 3: 223–242
   Web of Science ®Google Scholar
• Lenner P, Roos G, Johansson H, Lindh J, Dige U. Non‐Hodgkin's lymphoma: Multivariate analysis of prognostic factors including fraction of S‐phase cells. Acta Oncol 1987; 26: 179–183
   PubMed Web of Science ®Google Scholar
• Wooldridge T N, Grierson H L, Weisenburger D D, Armitage J O, Sanger W G, Collins M M, Pierson J L, Panza M E, Fordvce R, Purtilo D T. Association of DNA content and proliferative activity with clinical outcome in patients with diffuse mixed cell and large cell non‐Hodgkin's lymphoma. Cancer Res 1988; 48: 6608–6613
   PubMed Web of Science ®Google Scholar
• Macartney J C, Camplejohn R S, Moms R, Hollowood K, Clarke D, Timothy A. DNA flow cytometry of follic‐ular non‐Hodgkin's lymphoma. J Clin Patiol 1991; 44: 215–218
   PubMed Web of Science ®Google Scholar
• Lang W, Kienzle S, Diehl V. Proliferation kinetics of malignant non‐Hodekin's lvmDhomas related to histooatho‐logy of lymph node ‐biopsiks. Wrchows Arch A Pathol Anat Histopathol 1980; 389: 397–407
   PubMed Web of Science ®Google Scholar
• Sebo T J, Roche P C, Witzig T E, Kurtin P J. Proliferative activity in non‐Hodgkin's lymphomas. Am J Clin Pathol 1993; 99: 668–672
   PubMedGoogle Scholar
• Silvestrini R, Costa A, Boracchi P, Giardini R, Rilke F. Cell proliferation as a long‐term prognostic factor in diffuse large cell lymphomas. Int J Cancer 1993; 54: 231–236
   PubMed Web of Science ®Google Scholar
• Miller T P, Grogan T M, Dahlbexg S, Spier C M, Braziel R M, Banks P M, Foucar K, Kjetdsberg C R, Levy N, Nathwani B N, Schnitzer B, Tubbs R R, Gaynor E, Fisher R I. Prognostic significance of the Ki‐67‐ssociated proliferative antigen in aggressive non‐HodgIun's lymphomas: A prospective Southwest Oncology group trial. Blood 1994; 83(6)1460–1466
   PubMed Web of Science ®Google Scholar
• Winter J N, Andersen J, Variakojis D, Gordon L I, Fisher R I, Oken M M, Neiman R S, Jiang S, Bauer K D. Prognostic implications of ploidy and proliferative activity in the diffuse aggressive non‐Hodgkin's lymphomas. Blood 1996; 88: 3919–3925
   PubMed Web of Science ®Google Scholar
• Themeau T M, Grambsch P L, Fleming T R. Martingale based residuals for survival models. Biometrika 1990; 77: 147–160
   Web of Science ®Google Scholar
• Conover W J. Practical Nonparametric Statistics. Wiley, New York 1980
   Google Scholar
• Kaplan E L, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958; 53: 457–481
   Web of Science ®Google Scholar
• Mantel N. Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemother Rep 1966; 50: 163–170
   PubMedGoogle Scholar
• Cox D R. Regression models and life‐tables. J R Stat Soc [B] 1972; 34: 187–220
   Web of Science ®Google Scholar
• Mochen C, Giardini R, Costa A, Silvestrini R. MIB‐1 and S‐phase cell fraction predict survival in non‐Hodgkin's lymphomas. Cell Prolif 1997; 30: 37–47
   PubMed Web of Science ®Google Scholar
• Costa A, Silvestrini R, Giardini R, Messina‐Gabrielli G, Boracchi P, Veneroni S. Contribution of 3H‐thymi‐dine labelling index and flow cytometric S‐phase in predicting survival of patients with non‐Hodgkin's lymphoma. Br J Cancer 1992; 66: 680–684
   PubMed Web of Science ®Google Scholar
• Silvestrini R, Costa A, Veneroni S, Del‐Bino G, Persici P. Comparative analysis of different approaches to investigate cell kinetics. Cell Tissue Kinet 1988; 21: 123–131
   PubMedGoogle Scholar
• Greipp P, Witzig T, Gonchoroff N. Immunofluores‐cent plasma cell labeling indices (LI) using a monoclonal antibody (BU‐I). Am J Hematol 1985; 20: 289–292
   PubMed Web of Science ®Google Scholar
• Witzig T E, Habermann T M, Kurtin P J, Schroeder G, Stenson M J, Greipp P R. S‐phase fraction by the labeling index as a predictive factor for progression and survival in low grade non‐Hodgkin's lymphoma. Cancer 1995; 76: 1059–1064
   PubMed Web of Science ®Google Scholar
• Hall P A, Richards M A, Gregory W M, D'Ardenne A J, Lister T A, Stansfeld A G. The prognostic value of Ki‐67 immunostaining in non‐Hodgkin's lymphoma. J Pathol 1988; 154: 223–235
   PubMed Web of Science ®Google Scholar
• Grogan T M, Lippman S M, Spier C M, Slymen D J, Rybski J A, Rangel C S, Richter L C, Miller T P. Independent prognostic significance of a nuclear proliferation antigen in diffuse large cell lvmDhomas as determined by the monoclonal antibody Ki‐67. Blood 1988; 71: 1157–1160
   PubMed Web of Science ®Google Scholar